Like other medications with mu-opioid agonist activity, NUCYNTA® is contraindicated in people with substantial respiratory despair in unmonitored settings or maybe the absence of resuscitative devices.Initial marketed in Europe in 2011, tapentadol is becoming promoted as a combined mechanism of motion analgesic that's effective across a broad spec